An integrated treatment approach in patient with metastatic colorectal cancer and concomitant late cardiovascular complications of chemoradiotherapy for Hodgkin’s lymphoma. Clinical case
Open Access
- 11 September 2023
- journal article
- research article
- Published by Publishing House ABV Press in Oncohematology
- Vol. 18 (3) , 35-43
Abstract
The high efficacy of the currently used combined chemoradiotherapy for Hodgkin’s lymphoma not only significantly increased overall survival, but also made it possible for most patients to achieve the same quality of life as in a healthy population. at the same time, the problem of identifying late treatment complications, in particular cardiovascular the high efficacy of the currently used combined chemoradiotherapy for Hodgkin’s lymphoma not only significantly increased overall survival, but also made it possible for most patients to achieve the same quality of life as in a healthy population. at the same time, the problem of identifying late treatment complications, in particular cardiovascular diseases, remains an urgent problem, the timely diagnosis of which is an important task. the development of a second malignant neoplasm and the appointment of drug antitumor therapy with cardiotoxic agents necessitate a multidisciplinary approach. In the presented clinical observation, such tactics of patient management made it possible not only to timely identify late cardiovascular complications of Hodgkin’s lymphoma chemoradiotherapy, but also to conduct treatment for the second malignant disease with cardiotoxic agents with a positive antitumor effect.Keywords
This publication has 21 references indexed in Scilit:
- Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: A systematic review of incidence, manifestations and predisposing factorsCancer Treatment Reviews, 2013
- ABVD Alone versus Radiation-Based Therapy in Limited-Stage Hodgkin's LymphomaNew England Journal of Medicine, 2012
- Fluoropyrimidine-associated cardiotoxicity: revisitedExpert Opinion on Drug Safety, 2009
- Late Effects of Treatment for Hodgkin LymphomaJournal of the National Comprehensive Cancer Network, 2006
- Long-Term Cause-Specific Mortality of Patients Treated for Hodgkin’s DiseaseJournal of Clinical Oncology, 2003
- Pathophysiological effects of radiation on atherosclerosis development and progression, and the incidence of cardiovascular complicationsMedical Physics, 2002
- Long-Term Survival and Competing Causes of Death in Patients With Early-Stage Hodgkin’s Disease Treated at Age 50 or YoungerJournal of Clinical Oncology, 2002
- Long-Term Risk of Second Malignancy in Survivors of Hodgkin’s Disease Treated During Adolescence or Young AdulthoodJournal of Clinical Oncology, 2000
- Risk of Second Malignancy After Hodgkin’s Disease in a Collaborative British Cohort: The Relation to Age at TreatmentJournal of Clinical Oncology, 2000
- Cardiotoxicity of the Antiproliferative Compound FluorouracilDrugs, 1999